BioCentury
ARTICLE | Finance

Ebb & Flow

January 3, 2005 8:00 AM UTC

It's only rational that investors in a private company want a stepup when the company goes public. Indeed, anti-dilution provisions typically are attached to the preferred shares that are issued in venture rounds. But most of the time, these provisions are addressed before a company files its S-1, as the company and investors agree on a fixed ratio at which preferred shares convert into common stock. This makes it easy to figure out both how a company will be valued at its IPO and how investors will be diluted, because the only unknown variable is the price.

Things are not so simple with Sunesis' IPO, because there are two unknowns: the price and the number of shares that will be outstanding, which will vary depending on the price. Currently, the company has 40 million shares outstanding, but it plans to undertake a reverse split before the IPO, although the split ratio won't be determined until the IPO price is set...